Webb14 mars 2024 · “Simufilam is an innovative drug candidate that we are developing methodically, one study at a time,” Barbier said, adding that the company expects to … Webb10 maj 2024 · AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer’s disease.
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam …
Webb24 jan. 2024 · AUSTIN, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced positive top-line Phase 2 … Webb3 feb. 2024 · The investigational, oral small molecule treatment for Alzheimer disease (AD), simufilam, has shown in the results of an open-label study to be associated with the … georgia institute of technology 翻译
Simufilam C15H21N3O - PubChem
Webb6 aug. 2024 · A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks. Approximately 750 participants will be randomized (1:1) to receive either placebo or 100 mg tablets of simufilam, twice daily, for 52 weeks. Webb18 aug. 2024 · AUSTIN, Texas, Aug. 18, 2024(GLOBE NEWSWIRE) -- Cassava Sciences, Inc.(Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s … georgia institute of technology翻译